Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes
Authors' conclusion
GLP-1 RAs resulted in lower eGFR reduction compared with non-GLP-1 RAs and may contribute to better kidney graft survival after KTX.
Study context
- Population
- Kidney transplant recipients with T2D at a single facility, followed from 1 month post-transplantation for ≥24 months as of December 31, 2020
- Participants
- 73 vs 73
- Exposure
- GLP-1 RA vs other antidiabetic medications
- GLP-1 RAn = 73
- non-GLP-1 RAn = 73reference
- Outcome
- Sustained eGFR reduction of at least 40% from baseline for 4 months post-transplantation
Methodological detailspropensity score, inverse probability of treatment weighting, SGLT2i use as competing event
- Propensity score
- Inverse probability of treatment weighting
- SGLT2i use as competing event
Main finding
As reported in the abstract
Sustained eGFR reduction
GLP-1 RA
1
events
non-GLP-1 RA
6
events
Observational data: associations, not effects.
Original publication
Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes. J Clin Endocrinol Metab. Published 28 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →